Home » Stocks » ORGS

Orgenesis Inc. (ORGS)

Stock Price: $5.47 USD -0.10 (-1.80%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
After-hours: $5.59 +0.12 (2.19%) Jun 11, 7:01 PM
Market Cap 133.90M
Revenue (ttm) 15.16M
Net Income (ttm) 74.66M
Shares Out 24.19M
EPS (ttm) -2.79
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $5.47
Previous Close $5.57
Change ($) -0.10
Change (%) -1.80%
Day's Open 5.63
Day's Range 5.29 - 5.63
Day's Volume 105,518
52-Week Range 4.14 - 8.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Investigator-initiated, randomized, placebo-controlled, phase 2 trial to evaluate autologous stromal and vascular fraction cell (“SVF”) injections after rotator cuff surgery Investigator-initiated, rand...

3 days ago - GlobeNewsWire

GERMANTOWN, Md., June 01, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies...

1 week ago - GlobeNewsWire

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O), the cell and gene therapies (CGTs) focused biotech, reported a four-fold increase in revenue in its first quarter to end-March, as the company continues its journe...

1 month ago - Proactive Investors

Achieves operating profit for the first quarter of 2021

1 month ago - GlobeNewsWire

12:20pm: Pharmaceutical stocks fall The Dow was up 162 points, 0.5%, to 34,393 at midday. The Nasdaq was ticked down 7 points to 13,576, and the S&P 500 picked up 12 points, 0.3%, to 4,180.

Other stocks mentioned: AREC, BKLLF, BLONF, GRSLF, HLRTF, MBII, MRNA ...
1 month ago - Proactive Investors

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) is poised to carry out the first-in-human trial of its Tissue Genesis Icellator2 to treat Acute Respiratory Distress Syndrome (ARDS) caused by the coronavirus (COVI...

1 month ago - Proactive Investors

GERMANTOWN, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies,...

1 month ago - GlobeNewsWire

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) has announced a tie-up with Rome's Bambino Gesù children's hospital in Rome, Italy to establish a point-of-care cell therapy centre there.  Work will focus on suppo...

2 months ago - Proactive Investors

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) has announced a tie-up with Rome's Bambino Gesù children's hospital - the first such hospital in Italy - to establish a point-of-care cell therapy centre there.  Wo...

2 months ago - Proactive Investors

GERMANTOWN, Md., March 29, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapie...

2 months ago - GlobeNewsWire

Orgenesis Inc (NASDAQ:ORGS) announced Thursday that it is collaborating with MIDA Biotech BV to establish point-of-care centers at hospitals and other medical institutions across western Europe. Orgenes...

2 months ago - Proactive Investors

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) announced Thursday that it has entered the second phase of its collaboration with Hospital Infantil Universitario Niño Jesús in Madrid, Spain, focused on the hospit...

3 months ago - Proactive Investors

Global biotech unlocking the potential of personalized therapies and closed processing systems helpful in manufacturing Maryland-based firm has a Cell and Gene Therapy (CGT) Biotech platform The platfor...

3 months ago - Proactive Investors

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O), the cell and gene therapies (CGTs) focused biotech, told investors it expects revenue to more than double in 2021, based on its existing contracts alone.  In a sta...

3 months ago - Proactive Investors

12:48pm: Dow, Nasdaq headed in opposite directions The Dow was up 605 points, 1.9%, at 32,101 at midday, and the S&P 500 picked up 36 points, almost 1%, to 3,878 points. The Nasdaq, meanwhile, fell 57 p...

Other stocks mentioned: ALPP, BETRF, CYDY, DIS, EPWCF, EQTRF, GTBAF ...
3 months ago - Proactive Investors

Orgenesis Inc (NASDAQ:ORGS) (FRA:45O) announced Monday it has signed a collaboration agreement with Dong-a University Hospital in South Korea and Cure Therapeutics Inc to utilize Orgenesis Mobile Proces...

3 months ago - Proactive Investors

GERMANTOWN, Md., March 08, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapie...

3 months ago - GlobeNewsWire

GERMANTOWN, Md., March 04, 2021 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapie...

3 months ago - GlobeNewsWire

Orgenesis is a $151m market cap biotech focused on cell and gene therapy technologies. It has a technology, therapeutics, and point of care platform that enables its CGT partners to develop products in ...

4 months ago - Seeking Alpha

Reports rapid advancement of therapeutic pipeline

7 months ago - GlobeNewsWire

GERMANTOWN, Md., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies,...

7 months ago - GlobeNewsWire

Icellator® commercially available for lipotransfer in first two countries with more approvals expected Icellator® commercially available for lipotransfer in first two countries with more approvals expected

7 months ago - GlobeNewsWire

Acquisition to support accelerated commercialization of Koligo’s KYSLECEL®,  a personalized islet cell therapy available in the U.S. for chronic and recurrent acute pancreatitis

8 months ago - GlobeNewsWire

GERMANTOWN, Md., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene ther...

9 months ago - GlobeNewsWire

GERMANTOWN, Md., Aug. 20, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene thera...

9 months ago - GlobeNewsWire

Provides update on COVID-19 therapeutic programs

10 months ago - GlobeNewsWire

GERMANTOWN, Md., July 14, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and ...

10 months ago - GlobeNewsWire

GERMANTOWN, Md., June 29, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and...

11 months ago - GlobeNewsWire

GERMANTOWN, Md., June 22, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and...

11 months ago - GlobeNewsWire

GERMANTOWN, Md., June 10, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and ...

1 year ago - GlobeNewsWire

GERMANTOWN, Md., June 01, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and tr...

1 year ago - GlobeNewsWire

Collaboration project focused on clinical development and validation of Orgenesis’ immune-oncology cell therapies Collaboration project focused on clinical development and validation of Orgenesis’ immun...

1 year ago - GlobeNewsWire

GERMANTOWN, Md., May 15, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization and t...

1 year ago - GlobeNewsWire

Orgenesis (NASDAQ: ORGS) shares are trading higher on Wednesday. The company announced a cell-based vaccine platform targeting COVID-19 and other existing and emerging viral diseases.

1 year ago - Benzinga

Initiating a novel program targeting the virus and virus infected cells, using whole cell-based vaccines Initiating a novel program targeting the virus and virus infected cells, using whole cell-based v...

1 year ago - GlobeNewsWire

Cash and cash equivalents of $107.1 million as of March 31, 2020 Cash and cash equivalents of $107.1 million as of March 31, 2020

1 year ago - GlobeNewsWire

GERMANTOWN, Md., April 29, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization an...

1 year ago - GlobeNewsWire

GERMANTOWN, Md., April 27, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization and t...

1 year ago - GlobeNewsWire

Orgenesis Acquiring Tamir, And Other News: The Good, Bad And Ugly Of Biopharma

Other stocks mentioned: PSTI, TDOC
1 year ago - Seeking Alpha

Strategy to combine ranpirnase antiviral platform with Bioxome™ technology Strategy to combine ranpirnase antiviral platform with Bioxome™ technology

1 year ago - GlobeNewsWire

JV to utilize RevaTis’s patented technique to obtain mdMSCs through a minimally invasive muscle biopsy and leverage mdMSC manufacturing capability

1 year ago - GlobeNewsWire

Patented process results in uniform, scalable production and ability to deliver cell cargo similar to natural exosomes/EVs Patented process results in uniform, scalable production and ability to deliver...

1 year ago - GlobeNewsWire

GERMANTOWN, Md., March 30, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to lowering costs, accelerating comm...

1 year ago - GlobeNewsWire

GERMANTOWN, Md., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc. (NASDAQ: ORGS), a provider of point-of-care cell and gene therapy development, processing and treatment solutions (“POCare”), today an...

1 year ago - GlobeNewsWire

GERMANTOWN, Md., Feb. 03, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), today announced that Catalent Pharma Solutions has agreed to acquire Masthercell Glo...

1 year ago - GlobeNewsWire

GERMANTOWN, Md., Jan. 21, 2020 (GLOBE NEWSWIRE) -- Orgenesis Inc . (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO manufac...

1 year ago - GlobeNewsWire

First collaboration project focused on developing and commercializing lentiviral manufacturing system First collaboration project focused on developing and commercializing lentiviral manufacturing system

1 year ago - GlobeNewsWire

Milestone Payment from Great Point Partners Marks Second and Final Payment of its $25 Million Planned Investment Milestone Payment from Great Point Partners Marks Second and Final Payment of its $25 Mil...

1 year ago - GlobeNewsWire

Partnership to enable HYGEIA’s hospital network to develop and deliver onsite cell and gene therapies to patients Partnership to enable HYGEIA’s hospital network to develop and deliver onsite cell and g...

1 year ago - GlobeNewsWire

About ORGS

Orgenesis Inc., a biotech company, focusing on cell and gene therapies (CGTs). The company develops a Point of Care (POCare) platform includes three enabling components: a pipeline of licensed POCare Therapeutics that are processed and produced in closed, automated POCare Technology systems across a collaborative POCare Network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at t... [Read more...]

Industry
Biotechnology
Founded
2008
CEO
Vered Caplan
Employees
111
Stock Exchange
NASDAQ
Ticker Symbol
ORGS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for Orgenesis is 9.00, which is an increase of 64.53% from the latest price.

Price Target
$9.00
(64.53% upside)